Drug-Induced Vanishing Bile Duct Syndrome: From Pathogenesis to Diagnosis and Therapeutics

Semin Liver Dis. 2021 Aug;41(3):331-348. doi: 10.1055/s-0041-1729972. Epub 2021 Jun 15.

Abstract

The most concerned issue in the context of drug/herb-induced chronic cholestasis is vanishing bile duct syndrome. The progressive destruction of intrahepatic bile ducts leading to ductopenia is usually not dose dependent, and has a delayed onset that should be suspected when abnormal serum cholestasis enzyme levels persist despite drug withdrawal. Immune-mediated cholangiocyte injury, direct cholangiocyte damage by drugs or their metabolites once in bile, and sustained exposure to toxic bile salts when biliary epithelium protective defenses are impaired are the main mechanisms of cholangiolar damage. Current therapeutic alternatives are scarce and have not shown consistent beneficial effects so far. This review will summarize the current literature on the main diagnostic tools of ductopenia and its histological features, and the differential diagnostic with other ductopenic diseases. In addition, pathomechanisms will be addressed, as well as the connection between them and the supportive and curative strategies for ductopenia management.

Publication types

  • Review

MeSH terms

  • Bile Ducts
  • Bile Ducts, Intrahepatic
  • Biliary Tract*
  • Cholestasis* / chemically induced
  • Cholestasis* / diagnosis
  • Cholestasis* / therapy
  • Humans
  • Pharmaceutical Preparations*

Substances

  • Pharmaceutical Preparations